---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-038077"
form_type: "8-K"
ticker: "TMDX"
cik: "0001756262"
company_name: "TransMedics Group, Inc."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T08:56:17.621402+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# TransMedics Q2 revenue $52.5M, up 156% YoY; raises FY 2023 guidance to $180M-$190M

## Summary
- Net revenue $52.5M in Q2 2023, up 156% from $20.5M YoY; net loss narrowed to $1.0M from $11.5M.
- Full-year 2023 revenue guidance raised to $180M-$190M (93%-103% growth) from prior $160M-$170M.
- U.S. National OCS Program drove ~93% of OCS cases; cash $582.2M after $393M convertible notes offering.
- Gross margin steady at 70%; operating expenses $37.6M vs $24.1M; signed deal to acquire Summit Aviation.

## SEC filing metadata
- accession: 0000950170-23-038077
- form_type: 8-K
- ticker: TMDX
- cik: 0001756262
- company_name: TransMedics Group, Inc.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1756262/000095017023038077/0000950170-23-038077-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1756262/000095017023038077/tmdx-20230803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-038077
- JSON: https://secwatch.observer/filing/0000950170-23-038077.json
- Plain text: https://secwatch.observer/filing/0000950170-23-038077.txt

## Key facts
- Earnings Releases
  TransMedics Group, Inc. reported full year 2023 results: revenue $180 million to $190 million. Guidance raised.
  - Period: full year 2023
  - Revenue: $180 million to $190 million
  - Guidance: raised
  - Result: guidance update
  source text: TransMedics is updating its full year 2023 revenue guidance to be in the range of $180 million to $190 million, which represents 93% to 103% growth compared to the company’s prior year revenue. TransMedics’ prior 2023 revenue guidance was $160 million to $170 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1756262/000095017023038077/0000950170-23-038077-index.htm
- Earnings Releases
  TransMedics Group, Inc. reported quarter ended June 30, 2023 results: net income Net loss for the second quarter of 2023 was $1.0 million, compared to $11.5 million in the second quarter of 2022..
  - Period: quarter ended June 30, 2023
  - Net income: Net loss for the second quarter of 2023 was $1.0 million, compared to $11.5 million in the second quarter of 2022.
  - Result: reported results
  source text: Net revenue of $52.5 million in the second quarter of 2023, a 156% increase compared to the second quarter of 2022 .
  evidence_url: https://www.sec.gov/Archives/edgar/data/1756262/000095017023038077/0000950170-23-038077-index.htm
- Earnings Releases
  TransMedics Group, Inc. reported quarter ended June 30, 2023 results: net income Net loss for the second quarter of 2023 was $1.0 million, compared to $11.5 million in the second quarter of 2022..
  - Period: quarter ended June 30, 2023
  - Net income: Net loss for the second quarter of 2023 was $1.0 million, compared to $11.5 million in the second quarter of 2022.
  - Result: reported results
  source text: Net loss for the second quarter of 2023 was $1.0 million, compared to $11.5 million in the second quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1756262/000095017023038077/0000950170-23-038077-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.